Invention Grant
US07728040B1 Polyamine conjugates as selective NMDA inhibitors and anti-cancer drugs
失效
多胺缀合物作为选择性NMDA抑制剂和抗癌药物
- Patent Title: Polyamine conjugates as selective NMDA inhibitors and anti-cancer drugs
- Patent Title (中): 多胺缀合物作为选择性NMDA抑制剂和抗癌药物
-
Application No.: US12151823Application Date: 2008-05-09
-
Publication No.: US07728040B1Publication Date: 2010-06-01
- Inventor: Otto Phanstiel
- Applicant: Otto Phanstiel
- Applicant Address: US FL Orlando
- Assignee: University of Central Florids Research Foundation, Inc.
- Current Assignee: University of Central Florids Research Foundation, Inc.
- Current Assignee Address: US FL Orlando
- Agency: Law Offices of Brian S. Steinberger, P.A.
- Agent Brian S. Steinberger; Joyce P. Morlin
- Main IPC: A61K31/13
- IPC: A61K31/13

Abstract:
Polyamine compounds, method of synthesis and method of use for anti-cancer purposes, for enhancing the activity of existing anti-cancer drugs, as well as, for inhibiting N-Methyl-D-Aspartate (NMDA) receptors found in neurotransmission systems are provided. Certain polyamine motifs have been identified that can be attached to toxic agents to facilitate their access to cancer cells as well as polyamine compounds of surprising cytotoxicity with selectivity in killing cancer cells, and surprising utility in the treatment of Alzheimer's disease and brain stroke. It includes an illustrative conjugate system with examples of a triamine or a tetraamine appended to a cytotoxic agent. Included is a general strategy to enhance cell uptake by attaching a polyamine vectoring system with an example of a triamine vector attached to an existing anti-cancer drug to improve its chemotherapeutic potency. There is an illustration of tetraamine derivatives which have surprising enhanced selectivity in inhibiting N-methyl-D-aspartate (NMDA) receptors involved in neurotransmission. Several ligands can affect the activity of this receptor, which has been shown to initiate cell death under stroke conditions (lack of oxygen). Tetraamine derivatives which bind or inhibit the action of the NMDA receptor provide new therapy for NMDA-associated human diseases, such as Alzheimer's disease and stroke.
Information query